Mishpacha Holdings Corp Makes New Investment in United Therapeutics Corporation $UTHR

Mishpacha Holdings Corp acquired a new stake in United Therapeutics Corporation (NASDAQ:UTHR) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 1,000 shares of the biotechnology company’s stock, valued at approximately $487,000. United Therapeutics comprises approximately 0.4% of Mishpacha Holdings Corp’s investment portfolio, making the stock its 11th largest position.

Other large investors also recently modified their holdings of the company. Torren Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter worth about $26,000. Activest Wealth Management raised its holdings in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the period. WealthCollab LLC lifted its position in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the last quarter. Rakuten Securities Inc. lifted its position in United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the last quarter. Finally, Entrust Financial LLC bought a new stake in shares of United Therapeutics during the fourth quarter worth approximately $31,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

UTHR stock opened at $536.59 on Friday. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35. The business has a 50-day simple moving average of $564.47 and a 200 day simple moving average of $523.41. The company has a market cap of $22.78 billion, a PE ratio of 19.81, a price-to-earnings-growth ratio of 1.75 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm had revenue of $781.50 million for the quarter, compared to analyst estimates of $797.40 million. During the same quarter in the previous year, the company earned $6.63 earnings per share. The company’s quarterly revenue was down 1.6% on a year-over-year basis. On average, analysts anticipate that United Therapeutics Corporation will post 26.84 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction that occurred on Thursday, June 18th. The shares were sold at an average price of $541.55, for a total transaction of $4,494,865.00. Following the completion of the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $24,462,896.60. The trade was a 15.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $549.17, for a total transaction of $5,491,700.00. Following the transaction, the chief financial officer owned 18,876 shares of the company’s stock, valued at approximately $10,366,132.92. This represents a 34.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 644,468 shares of company stock valued at $364,004,497. Company insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on UTHR. Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Royal Bank Of Canada lowered their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Bank of America lifted their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a report on Tuesday, March 31st. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Oppenheimer upped their price target on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.